Identification

Name
Alprenolol
Accession Number
DB00866  (APRD00736)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.

Structure
Thumb
Synonyms
  • (RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol
  • 1-(2-Allylphenoxy)-3-isopropylamino-2-propanol
  • 1-(O-Allylphenoxy)-3-(isopropylamino)-2-propanol
  • Alfeprol
  • Alprenolol
  • Alprénolol
  • Alprenololum
  • Aprenololo
External IDs
H 56/28 / H 561/28
Product Ingredients
IngredientUNIICASInChI Key
Alprenolol hydrochloride2502C2OIRK13707-88-5RRCPAXJDDNWJBI-UHFFFAOYSA-N
International/Other Brands
Apllobal (AstraZeneca) / Aptin (AstraZeneca) / Aptine / Aptol Duriles / Atenenol (Tsuruhara Seiyaku) / Elp (Shyh Dar) / Gubernal / Regletin / Skajilol (Kotobuki Seiyaku) / Yobir
Categories
UNII
877K5MQ27W
CAS number
13655-52-2
Weight
Average: 249.3486
Monoisotopic: 249.172878985
Chemical Formula
C15H23NO2
InChI Key
PAZJSJFMUHDSTF-UHFFFAOYSA-N
InChI
InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
IUPAC Name
1-[2-(prop-2-en-1-yl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC=C1CC=C

Pharmacology

Indication

For the treatment of hypertension, angina, and arrhythmia

Structured Indications
Not Available
Pharmacodynamics

Alprenolol is a non-selective beta-blocker used in the treatment of hypertension, edema, ventricular tachycardias, and atrial fibrillation. Alprenolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Alprenolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Alprenolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, alprenolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Mechanism of action

Alprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
antagonist
Human
A5-hydroxytryptamine receptor 1A
antagonist
Human
UBeta-3 adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

80-90%

Metabolism

Hepatic. One of the active metabolites, 4-OH-alprenolol, is an active beta-blocker.

Route of elimination
Not Available
Half life

2-3 hours

Clearance
Not Available
Toxicity

LD50=597.0 mg/kg (Orally in rats)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Alprenolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Alprenolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Alprenolol.Experimental
AbirateroneThe serum concentration of Alprenolol can be increased when it is combined with Abiraterone.Approved
AcebutololAlprenolol may increase the hypotensive activities of Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Alprenolol.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Alprenolol.Approved
AcetohexamideAlprenolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Acetylcholine.Approved
AcetyldigitoxinAlprenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinAlprenolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Alprenolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Experimental, Investigational
AlaproclateThe serum concentration of Alprenolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Alprenolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Alprenolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
AliskirenAlprenolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Alprenolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Alprenolol.Approved
AmbrisentanAlprenolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateAlprenolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineAlprenolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophyllineAlprenolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Alprenolol.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Alprenolol.Approved
AmobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Alprenolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Alprenolol.Approved, Illicit
AndrographolideAndrographolide may decrease the antihypertensive activities of Alprenolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Alprenolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Alprenolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Alprenolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
ArbutamineAlprenolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Arecoline.Experimental
ArformoterolAlprenolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
ArtemetherThe metabolism of Alprenolol can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the hypotensive activities of Alprenolol.Approved
AtomoxetineThe metabolism of Alprenolol can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Alprenolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Alprenolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Alprenolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
BambuterolAlprenolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Alprenolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Barbital.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Alprenolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Alprenolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Alprenolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Alprenolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Alprenolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Alprenolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Alprenolol.Approved
BepridilAlprenolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Alprenolol can be decreased when combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Alprenolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Alprenolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Alprenolol.Experimental
BimatoprostAlprenolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Alprenolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Alprenolol.Investigational
BosentanBosentan may increase the hypotensive activities of Alprenolol.Approved, Investigational
BQ-123Alprenolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumAlprenolol may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Alprenolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Alprenolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Alprenolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Alprenolol.Investigational
BucindololAlprenolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Alprenolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Alprenolol.Experimental
BunazosinAlprenolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Alprenolol.Approved, Investigational
BupranololAlprenolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Alprenolol can be decreased when combined with Bupropion.Approved
CabergolineAlprenolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Alprenolol.Experimental
CafedrineAlprenolol may increase the hypotensive activities of Cafedrine.Investigational
CandesartanAlprenolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Alprenolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Alprenolol.Experimental
CaptoprilAlprenolol may increase the hypotensive activities of Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Alprenolol is combined with Carbachol.Approved
CarbutamideAlprenolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Alprenolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Alprenolol.Approved
CarvedilolAlprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Alprenolol.Experimental
CelecoxibThe metabolism of Alprenolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololAlprenolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Alprenolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideAlprenolol may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Alprenolol.Experimental
ChlorpromazineThe metabolism of Alprenolol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideAlprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Alprenolol.Approved
CholecalciferolThe metabolism of Alprenolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Alprenolol.Approved
CicletanineAlprenolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilAlprenolol may increase the hypotensive activities of Cilazapril.Approved
CimetidineThe metabolism of Alprenolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Alprenolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Alprenolol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Alprenolol can be decreased when combined with Clemastine.Approved
ClenbuterolAlprenolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClobazamThe metabolism of Alprenolol can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Alprenolol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Alprenolol.Approved
CloranololAlprenolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Alprenolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Alprenolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Alprenolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Alprenolol can be decreased when combined with Cocaine.Approved, Illicit
CoumaphosCoumaphos may increase the bradycardic activities of Alprenolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Alprenolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Alprenolol.Investigational
CyclopenthiazideAlprenolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Alprenolol.Approved
CymarinAlprenolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Alprenolol.Investigational
DapoxetineThe serum concentration of Alprenolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Alprenolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Alprenolol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Alprenolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Alprenolol.Approved
DelaprilAlprenolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Alprenolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Alprenolol.Approved
DeserpidineAlprenolol may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe metabolism of Alprenolol can be decreased when combined with Desipramine.Approved
DeslanosideAlprenolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Alprenolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Alprenolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Alprenolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
diethylnorspermineAlprenolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Alprenolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Alprenolol.Approved
DigitoxinAlprenolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinAlprenolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Alprenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Alprenolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Alprenolol.Approved
DiphenhydramineThe metabolism of Alprenolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Alprenolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Alprenolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Alprenolol.Experimental
DobutamineAlprenolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Alprenolol.Approved
DorzolamideAlprenolol may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Alprenolol can be decreased when combined with Dosulepin.Approved
DoxazosinAlprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Alprenolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Alprenolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
DuloxetineThe metabolism of Alprenolol can be decreased when combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Alprenolol.Investigational
DyphyllineAlprenolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Alprenolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Alprenolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Alprenolol.Approved
EfonidipineAlprenolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Alprenolol can be decreased when combined with Eliglustat.Approved
EnalaprilEnalapril may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
EnalaprilatAlprenolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Alprenolol.Experimental
EpanololAlprenolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Alprenolol.Approved
EpoprostenolAlprenolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAlprenolol may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAlprenolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Alprenolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Alprenolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
EtoperidoneThe serum concentration of Alprenolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Alprenolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Alprenolol.Experimental
FelodipineAlprenolol may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Alprenolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Alprenolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Alprenolol.Approved
FenoterolAlprenolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Alprenolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Alprenolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Alprenolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Alprenolol.Experimental
Ferulic acidAlprenolol may increase the hypotensive activities of Ferulic acid.Experimental
FingolimodAlprenolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Alprenolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Alprenolol.Experimental
FluoxetineThe metabolism of Alprenolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Alprenolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
FluvoxamineThe metabolism of Alprenolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolAlprenolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Alprenolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Alprenolol.Approved, Investigational, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Alprenolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Alprenolol.Approved
GitoformateAlprenolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideAlprenolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideAlprenolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAlprenolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAlprenolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAlprenolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideAlprenolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideAlprenolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Alprenolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Alprenolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Alprenolol.Approved
GuanazodineAlprenolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineAlprenolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
GuanoclorAlprenolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAlprenolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAlprenolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Alprenolol can be decreased when combined with Haloperidol.Approved
HarmalineHarmaline may increase the hypotensive activities of Alprenolol.Experimental
HexamethoniumAlprenolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Alprenolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Alprenolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Alprenolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Alprenolol.Approved
HydrochlorothiazideAlprenolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Alprenolol.Approved, Investigational
HydroxychloroquineThe metabolism of Alprenolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Alprenolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Alprenolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Alprenolol.Approved
IloprostIloprost may increase the hypotensive activities of Alprenolol.Approved, Investigational
ImidaprilAlprenolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Alprenolol.Experimental
ImipramineThe metabolism of Alprenolol can be decreased when combined with Imipramine.Approved
IndacaterolAlprenolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Alprenolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Alprenolol.Approved
IndenololAlprenolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Alprenolol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Alprenolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Alprenolol.Withdrawn
IndoraminAlprenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanAlprenolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkAlprenolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Alprenolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Alprenolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Alprenolol.Withdrawn
IrbesartanAlprenolol may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Alprenolol.Approved
IsoetarineAlprenolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Alprenolol.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Alprenolol can be decreased when combined with Isoniazid.Approved
IsoprenalineAlprenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Alprenolol.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Alprenolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Alprenolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Alprenolol.Investigational
KetoconazoleThe metabolism of Alprenolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Alprenolol.Approved
LabetalolAlprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineAlprenolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CAlprenolol may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Alprenolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Alprenolol.Approved, Investigational
LevomilnacipranThe serum concentration of Alprenolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
LevosalbutamolAlprenolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Alprenolol.Approved, Vet Approved
LinsidomineAlprenolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Alprenolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Alprenolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Alprenolol.Experimental
LopinavirThe metabolism of Alprenolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Alprenolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Alprenolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
LumefantrineThe metabolism of Alprenolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
MacitentanAlprenolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Alprenolol.Approved
MalathionMalathion may increase the bradycardic activities of Alprenolol.Approved, Investigational
ManidipineAlprenolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Alprenolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Alprenolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Alprenolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Alprenolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Alprenolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Alprenolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Alprenolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Alprenolol.Approved, Investigational
MetahexamideAlprenolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Alprenolol.Investigational, Withdrawn
MethacholineAlprenolol may increase the bronchoconstrictory activities of Methacholine.Approved
MethadoneThe metabolism of Alprenolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Alprenolol.Investigational
MethohexitalThe serum concentration of Alprenolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineAlprenolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Alprenolol can be decreased when combined with Methotrimeprazine.Approved
MethyldopaAlprenolol may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Alprenolol.Approved, Investigational
MethylergometrineAlprenolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinAlprenolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololAlprenolol may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Alprenolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Alprenolol.Approved
MetoprololThe metabolism of Alprenolol can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineAlprenolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilAlprenolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineAlprenolol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Alprenolol can be decreased when combined with Midostaurin.Approved
MilnacipranThe serum concentration of Alprenolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Alprenolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Alprenolol.Approved
MirabegronThe metabolism of Alprenolol can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Alprenolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Alprenolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Alprenolol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Alprenolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Alprenolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Alprenolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Alprenolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
MuzolimineAlprenolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Alprenolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Alprenolol.Approved
NadololAlprenolol may increase the hypotensive activities of Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Alprenolol.Approved
NaftopidilAlprenolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
NebivololAlprenolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Alprenolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Alprenolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Alprenolol.Approved
NevirapineThe metabolism of Alprenolol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Alprenolol.Withdrawn
NicardipineThe metabolism of Alprenolol can be decreased when combined with Nicardipine.Approved
NicorandilAlprenolol may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Alprenolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Alprenolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Alprenolol.Approved
NiguldipineAlprenolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Alprenolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineAlprenolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Alprenolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Alprenolol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Alprenolol.Approved
NitrendipineAlprenolol may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Alprenolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Alprenolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
ObinutuzumabAlprenolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Alprenolol.Withdrawn
OleandrinAlprenolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Alprenolol.Approved, Investigational
OlodaterolAlprenolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Alprenolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Alprenolol.Approved
OmapatrilatAlprenolol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineAlprenolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Alprenolol.Vet Approved
OuabainAlprenolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Alprenolol.Approved
OxprenololAlprenolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
PanobinostatThe serum concentration of Alprenolol can be increased when it is combined with Panobinostat.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Alprenolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Alprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Alprenolol.Approved
ParoxetineThe metabolism of Alprenolol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Alprenolol.Investigational
Peginterferon alfa-2bThe serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAlprenolol may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumAlprenolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Alprenolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Alprenolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Alprenolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Alprenolol.Approved
PeruvosideAlprenolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Alprenolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Alprenolol.Withdrawn
PhenobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineAlprenolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Alprenolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Alprenolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Alprenolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Alprenolol.Withdrawn
PindololAlprenolol may increase the hypotensive activities of Pindolol.Approved
PirbuterolAlprenolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Alprenolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Alprenolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Alprenolol.Withdrawn
Platelet Activating FactorAlprenolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideAlprenolol may increase the hypotensive activities of Polythiazide.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Alprenolol.Experimental, Investigational
PrazosinAlprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Alprenolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Alprenolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Alprenolol.Approved
ProcaterolAlprenolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Alprenolol.Experimental
PromazineThe metabolism of Alprenolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Alprenolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
PropafenoneThe serum concentration of Alprenolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Alprenolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Alprenolol.Vet Approved
PropranololPropranolol may increase the hypotensive activities of Alprenolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Alprenolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Alprenolol.Experimental
ProscillaridinAlprenolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Alprenolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Alprenolol.Approved
QuinaprilAlprenolol may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Alprenolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Alprenolol.Approved
RamiprilRamipril may increase the hypotensive activities of Alprenolol.Approved
RanolazineThe metabolism of Alprenolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Alprenolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Alprenolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Alprenolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Alprenolol.Approved
RescinnamineAlprenolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Alprenolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Alprenolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Alprenolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Alprenolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Alprenolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Alprenolol.Investigational
RiociguatAlprenolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
RitodrineAlprenolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Alprenolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabAlprenolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineAlprenolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Alprenolol.Investigational, Withdrawn
RolapitantThe metabolism of Alprenolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Alprenolol.Withdrawn
SalbutamolAlprenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Alprenolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
SalmeterolAlprenolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Alprenolol.Approved
SaprisartanAlprenolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Alprenolol.Approved, Investigational, Vet Approved
SelexipagAlprenolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Alprenolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Alprenolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Alprenolol.Investigational
SertralineThe metabolism of Alprenolol can be decreased when combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Alprenolol.Approved, Investigational
SilodosinAlprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanAlprenolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilAlprenolol may increase the hypotensive activities of Spirapril.Approved
SRT501SRT501 may decrease the antihypertensive activities of Alprenolol.Investigational
StiripentolThe metabolism of Alprenolol can be decreased when combined with Stiripentol.Approved
SufentanilSufentanil may increase the bradycardic activities of Alprenolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Alprenolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Alprenolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Alprenolol.Experimental
TacrineTacrine may increase the bradycardic activities of Alprenolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Alprenolol.Approved, Investigational
TalinololAlprenolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinAlprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Alprenolol.Investigational
TelmisartanAlprenolol may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilAlprenolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Alprenolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Alprenolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Alprenolol.Vet Approved
TerazosinAlprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Alprenolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineAlprenolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Alprenolol.Approved
TerlipressinAlprenolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineAlprenolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineAlprenolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineAlprenolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Alprenolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Alprenolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Alprenolol.Withdrawn
ThiopentalThe serum concentration of Alprenolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Alprenolol.Approved
ThioridazineThe metabolism of Alprenolol can be decreased when combined with Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Alprenolol.Approved
TiboloneAlprenolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Alprenolol can be decreased when combined with Ticlopidine.Approved
TicrynafenAlprenolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Alprenolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Alprenolol.Investigational
TipranavirThe metabolism of Alprenolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
TolazamideAlprenolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
TolbutamideAlprenolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Alprenolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Alprenolol.Approved
TolonidineAlprenolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Alprenolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Alprenolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Alprenolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Alprenolol.Experimental
TranylcypromineThe metabolism of Alprenolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Alprenolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Alprenolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Alprenolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Alprenolol.Vet Approved
TrichlormethiazideAlprenolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Alprenolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
TrimazosinAlprenolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Alprenolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Alprenolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Alprenolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Alprenolol.Approved, Investigational
UnoprostoneAlprenolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilAlprenolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Alprenolol.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Alprenolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Alprenolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Alprenolol can be decreased when combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Alprenolol.Approved
VilanterolAlprenolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineAlprenolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineAlprenolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideAlprenolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Alprenolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Alprenolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Alprenolol can be decreased when combined with Ziprasidone.Approved
ZofenoprilAlprenolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Alprenolol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

http://www.google.com.mx/patents/US3466376

General References
  1. Hold KM, de Boer D, Bos KL, van Ooijen RD, Zuidema J, Maes RA: Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. J Chromatogr Sci. 1996 Jan;34(1):13-9. [PubMed:8586675]
  2. Himori N, Ishimori T, Izumi A, Hiramatsu Y: Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. [PubMed:15525]
External Links
Human Metabolome Database
HMDB15004
KEGG Drug
D07156
PubChem Compound
2119
PubChem Substance
46506033
ChemSpider
2035
BindingDB
25764
ChEBI
51211
ChEMBL
CHEMBL266195
Therapeutic Targets Database
DAP000941
PharmGKB
PA164750541
Drugs.com
Drugs.com Drug Page
Wikipedia
Alprenolol
ATC Codes
C07AA01 — Alprenolol
MSDS
Download (28.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3466376No1966-06-171986-06-17Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)107-109 °CPhysProp
water solubility547 mg/LNot Available
logP3.10HANSCH,C ET AL. (1995)
Caco2 permeability-4.62ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP2.59ALOGPS
logP2.69ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability29.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9831
Blood Brain Barrier-0.9394
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6064
P-glycoprotein inhibitor IInhibitor0.5066
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8305
CYP450 2C9 substrateNon-substrate0.824
CYP450 2D6 substrateSubstrate0.882
CYP450 3A4 substrateNon-substrate0.7469
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8839
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9106
BiodegradationNot ready biodegradable0.9646
Rat acute toxicity2.5069 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8664
hERG inhibition (predictor II)Non-inhibitor0.6946
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (3.94 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Ether / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amino compound (CHEBI:51211)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Surman AJ, Doggrell SA: Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria. J Cardiovasc Pharmacol. 1993 Jan;21(1):35-9. [PubMed:7678677]
  2. De Ponti F, Cosentino M, Costa A, Girani M, Gibelli G, D'Angelo L, Frigo G, Crema A: Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors. Br J Pharmacol. 1995 Apr;114(7):1447-53. [PubMed:7606348]
  3. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]
  4. Brahmadevara N, Shaw AM, MacDonald A: Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol. 2003 Jan;138(1):99-106. [PubMed:12522078]
  5. Im MJ, Holzhofer A, Bottinger H, Pfeuffer T, Helmreich EJ: Interactions of pure beta gamma-subunits of G-proteins with purified beta 1-adrenoceptor. FEBS Lett. 1988 Jan 25;227(2):225-9. [PubMed:2828119]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Brodde OE, Wang XL, O'Hara N, Daul A, Schiess W: Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. [PubMed:2439825]
  2. Brodde OE, Daul A, Stuka N, O'Hara N, Borchard U: Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity". Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):417-22. [PubMed:2859531]
  3. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Millan MJ, Rivet JM, Canton H, Lejeune F, Bervoets K, Brocco M, Gobert A, Lefebvre de Ladonchamps B, Le Marouille-Girardon S, Verriele L, et al.: S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):451-63. [PubMed:1323650]
  2. Darmani NA: Role of the inhibitory adrenergic alpha 2 and serotonergic 5-HT1A components of cocaine's actions on the DOI-induced head-twitch response in 5-HT2-receptor supersensitive mice. Pharmacol Biochem Behav. 1993 Jun;45(2):269-74. [PubMed:8392199]
  3. Kuipers W, Link R, Standaar PJ, Stoit AR, Van Wijngaarden I, Leurs R, Ijzerman AP: Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. Mol Pharmacol. 1997 May;51(5):889-96. [PubMed:9145928]
  4. Misane I, Johansson C, Ogren SO: Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat. Br J Pharmacol. 1998 Oct;125(3):499-509. [PubMed:9806333]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 17:18